Encyclopedia of Gerontology and Population Aging

Living Edition
| Editors: Danan Gu, Matthew E. Dupre


  • Gülistan BahatEmail author
  • Tuğba Erdoğan
Living reference work entry

Latest version View entry history

DOI: https://doi.org/10.1007/978-3-319-69892-2_541-2


The word sarcopenia originates from the Greek words sarx (muscle) and -penia (loss). Sarcopenia is a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality.


Sarcopenia increases risk of falls and fractures, impairs ability to perform activities of daily living, leads to mobility disorders and loss of independence, impairs quality of life, and increases need for long-term care placement and death. It increases risk for hospitalization and the cost. It is observed more prevalent by aging, but many other factors contribute and increase risk of developing sarcopenia involving systemic diseases especially organ failures, inflammatory conditions, physical inactivity, nutritional deficiencies, and unhealthy food choices. Hence, sarcopenia may be associated with many prevalent diseases such as cardiac/respiratory/renal diseases, malignancies, and...

This is a preview of subscription content, log in to check access.


  1. Anagnostis P, Dimopoulou C, Karras S et al (2015) Sarcopenia in post-menopausal women: is there any role for vitamin D? Maturitas 82(1):56–64CrossRefGoogle Scholar
  2. Bahat G, Tufan A, Kilic C et al (2018a) Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality. Aging Male 5:1–7.  https://doi.org/10.1080/13685538.2018.1511976CrossRefGoogle Scholar
  3. Bahat G, Yilmaz O, Kılıç C et al (2018b) Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging 22(8):898–903CrossRefGoogle Scholar
  4. Bahat G, Kilic C, Ilhan B et al (2019) Association of different bioimpedanciometry estimations of muscle mass with functional measures. Geriatr Gerontol Int (in press)Google Scholar
  5. Baumgartner R, Koehler K, Gallagher D et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763CrossRefGoogle Scholar
  6. Beaudart C, Locquet M, Bornheim S et al (2018) French translation and validation of the sarcopenia screening tool SARC-F. Eur Geriatr Med 9:29.  https://doi.org/10.1007/s41999-017-0007-1CrossRefGoogle Scholar
  7. Blackman MR, Sorkin JD, Munzer T et al (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288(18):2282–2292CrossRefGoogle Scholar
  8. Buckinx F, Landi F, Cesari M et al (2018) Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle 9:269–278CrossRefGoogle Scholar
  9. Cawthon PM, Peters KW, Shardell MD et al (2014) Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci 69(5):567–575.  https://doi.org/10.1093/gerona/glu023CrossRefGoogle Scholar
  10. Cawthon PM, Travison TG, Manini TM et al (2019) Sarcopenia definition and outcomes consortium conference participants. Establishing the link between lean mass and grip strength cut-points with mobility disability and other health outcomes: proceedings of the sarcopenia definition and outcomes consortium conference. J Gerontol A Biol Sci Med Sci 14:glz081.  https://doi.org/10.1093/gerona/glz081CrossRefGoogle Scholar
  11. Critchley M (1931) The neurology of old age. Lancet 1:1221–1230CrossRefGoogle Scholar
  12. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 39(4):412–423.  https://doi.org/10.1093/ageing/afq034.CrossRefGoogle Scholar
  13. Cruz-Jentoft AJ, Landi F, Schneider SM et al (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the international sarcopenia initiative (EWGSOP and IWGS). Age Ageing 43(6):748–759.  https://doi.org/10.1093/ageing/afu115CrossRefGoogle Scholar
  14. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Writing Group for the European Working Group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31.  https://doi.org/10.1093/ageing/afy169CrossRefGoogle Scholar
  15. De Spiegeleer A, Beckwée D, Bautmans I et al (2018) Sarcopenia guidelines development group of the Belgian Society of Gerontology and Geriatrics (BSGG). Pharmacological interventions to improve muscle mass, muscle strength and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. Drugs Aging 35(8):719–734.  https://doi.org/10.1007/s40266-018-0566-y.CrossRefGoogle Scholar
  16. Dent E, Morley JE, Cruz-Jentoft AJ et al (2018) International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging 22(10):1148–1161.  https://doi.org/10.1007/s12603-018-1139-9CrossRefGoogle Scholar
  17. Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495CrossRefGoogle Scholar
  18. Fielding RA, Vellas B, Evans WJ et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249–256CrossRefGoogle Scholar
  19. Garcia JM, Boccia RV, Graham CD et al (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16(1):108–116CrossRefGoogle Scholar
  20. Hamaguchi Y, Kaido T, Okumura S et al (2017) Impact of skeletal muscle mass index, intramuscular adipose tissue content, and visceral to subcutaneous adipose tissue area ratio on early mortality of living donor liver transplantation. Transplantation 101(3):565–574CrossRefGoogle Scholar
  21. Heymsfield SB, Gonzalez MC, Lu J et al (2015) Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc 74:355–366CrossRefGoogle Scholar
  22. Ibrahim K, May C, Patel HP et al (2016) A feasibility study of implementing grip strength measurement into routine hospital practice (GRImP): study protocol. Pilot Feasibility Study 2:27CrossRefGoogle Scholar
  23. Ishii S, Tanaka T, Shibasaki K et al (2014) Development of a simple screening test for sarcopenia in older adults. Geriatr Gerontol Int. 2014 14(Suppl 1):93–101CrossRefGoogle Scholar
  24. Isidori AM, Giannetta E, Greco EA et al (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 63(3):280–293CrossRefGoogle Scholar
  25. Janssen I, Heymsfield SB, Ross R (2002) Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50:889–896CrossRefGoogle Scholar
  26. Kim MJ, Morley JE (2005) The hormonal fountains of youth: myth or reality. J Endocrinol Investig 28(11 Suppl Proceedings):5–14Google Scholar
  27. Kittiskulnam P, Carrero JJ, Chertow GM et al (2017) Sarcopenia among patients receiving hemodialysis: weighing the evidence. J Cachexia Sarcopenia Muscle 8(1):57–68.  https://doi.org/10.1002/jcsm.12130CrossRefGoogle Scholar
  28. Leong DP, Teo KK, Rangarajan S et al (2015) Prognostic value of grip strength: findings from the prospective urban rural epidemiology (PURE) study. Lancet 386:266–273CrossRefGoogle Scholar
  29. Liu CJ, Latham NK (2009) Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev (3):CD002759.  https://doi.org/10.1002/14651858.CD002759
  30. Masanes F, Rojano ILX, Salva A et al (2017) Cut-off points for muscle mass – not grip strength or gait speed – determine variations in sarcopenia prevalence. J Nutr Health Aging 21:825–829CrossRefGoogle Scholar
  31. McGregor RA, Cameron-Smith D, Poppitt SD (2014) It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan 3:9Google Scholar
  32. Morley JE, Abbatecola AM, Argiles JM et al (2011) Society on sarcopenia, cachexia and wasting disorders trialist workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 12(6):403–409.  https://doi.org/10.1016/j.jamda.2011.04.014CrossRefGoogle Scholar
  33. Muscaritoli M, Anker SD, Argiles J et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29(2):154–159CrossRefGoogle Scholar
  34. Newman A, Kupelian V, Visser M et al (2003) Sarcopenia: alternative definitions and association with lower extremity function. J Am Geriatr Soc 51:1602–1609CrossRefGoogle Scholar
  35. Paddon-Jones D, Rasmussen BB (2009) Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care 12(1):86–90.  https://doi.org/10.1097/MCO.0b013e32831cef8bCrossRefGoogle Scholar
  36. Rolland Y, Lauwers-Cances V, Pahor M et al (2004) Muscle strength in obese elderly women: effect of recreational physical activity in a cross-sectional study. Am J Clin Nutr 79:552–557CrossRefGoogle Scholar
  37. Rosenberg IH (1989) Summary comments: epidemiologic and methodologic problems in determining nutritional status of older persons. Am J Clin Nutr 50:1231–1233CrossRefGoogle Scholar
  38. Snyder P, Bhasin S, Cunningham G et al (2016) Effects of testosterone treatment in older men. N Engl J Med 374(7):611–624CrossRefGoogle Scholar
  39. Studenski SA, Peters KW, Alley DE et al (2014) The FNIH sarcopenia project: rationale and study description. J Gerontol A Biol Sci Med Sci 5:547–558CrossRefGoogle Scholar
  40. Sumukadas D, Witham MD, Struthers AD (2007) Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 177:867–874CrossRefGoogle Scholar
  41. Trevino-Aguirre E, Lopez-Teros T, Gutierrez-Robledo L et al (2014) Availability and use of dual energy X-ray absorptiometry (DXA) and bio-impedance analysis (BIA) for the evaluation of sarcopenia by Belgian and Latin American geriatricians. J Cachexia Sarcopenia Muscle 5:79–81CrossRefGoogle Scholar
  42. Yamada Y, Nishizawa M, Uchiyama T et al (2017) Developing and validating an age-independent equation using multi-frequency bioelectrical impedance analysis for estimation of appendicular skeletal muscle mass and establishing a cutoff for sarcopenia. Int J Environ Res Public Health 14.  https://doi.org/10.3390/ijerph14070809.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Istanbul University, Istanbul Medical SchoolDepartment of Internal Medicine, Division of GeriatricsIstanbulTurkey

Section editors and affiliations

  • M. Cristina Polidori
    • 1
  1. 1.Ageing Clinical ResearchUniversity Hospital of CologneKölnGermany